Article type: Opinion

Issue URL: https://www.alliedacademies.org/food-technology-and-preservation/

Unveiling diabetic cardiomyopathy: Pathophysiology and clinical implications.

Amey chohan*

Department of Community Health Sciences, University of Calgary, Canada

***Correspondence to:** Amey chohan, Department of Community Health Sciences, University of Calgary, Canada ,E-mail: amychn@aca

Received: *01-Mar-2025, Manuscript No. AADY-25-166640;* ***Editor assigned:*** *03-Mar-2025, PreQC No. AADY-25-166640(PQ);* ***Reviewed:*** *16-Mar-2025, QC No. AADY-25-166640;* ***Revised:*** *22-Mar-2025, Manuscript No. AADY-25-166640(R);* ***Published:*** *25-Mar-2024,DOI:10.35841/aady-9.1.249*

Introduction

Diabetic cardiomyopathy (DCM) is a distinct cardiac disorder that occurs in patients with diabetes mellitus, characterized by structural and functional abnormalities of the myocardium independent of other cardiovascular risk factors such as hypertension or coronary artery disease. Over recent decades, DCM has gained increasing recognition due to the rising global prevalence of diabetes and its significant impact on cardiovascular morbidity and mortality. Understanding the pathophysiology of diabetic cardiomyopathy and its clinical implications is critical for early diagnosis, effective management, and improving patient outcomes.

In diabetes, chronic hyperglycemia leads to increased fatty acid utilization by cardiomyocytes at the expense of glucose metabolism. This metabolic shift causes an energy imbalance, with excessive fatty acid oxidation generating toxic lipid intermediates and reactive oxygen species (ROS). The resulting lipotoxicity and oxidative stress damage mitochondrial function, impairing ATP production, which is vital for myocardial contractility.

Insulin resistance, a hallmark of type 2 diabetes, disrupts normal insulin signaling in cardiac tissue. This impairment reduces glucose uptake by cardiomyocytes, exacerbating energy deficits and promoting harmful metabolic by-products. Insulin resistance also alters cellular growth and survival pathways, contributing to myocardial cell hypertrophy and apoptosis.

Chronic hyperglycemia promotes non-enzymatic glycation of proteins and lipids, forming AGEs. These molecules accumulate in cardiac tissue and cross-link with collagen, increasing myocardial stiffness and reducing elasticity. AGEs also bind to receptors (RAGEs), triggering inflammatory cascades and fibrosis within the myocardium.

Diabetes induces a chronic low-grade inflammatory state, with elevated cytokines such as TNF-α and IL-6. This inflammatory milieu stimulates cardiac fibroblasts, resulting in excessive deposition of extracellular matrix proteins and myocardial fibrosis. Fibrosis impairs ventricular relaxation, leading to diastolic dysfunction, a key early feature of DCM.

Diabetes damages the coronary microcirculation through endothelial dysfunction and capillary rarefaction. Reduced nitric oxide bioavailability and increased oxidative stress cause impaired vasodilation, leading to myocardial ischemia and further cardiac remodeling.

Diabetic autonomic neuropathy affects heart rate variability and cardiac autonomic regulation, contributing to arrhythmias and impaired myocardial performance.

Collectively, these mechanisms cause left ventricular hypertrophy, myocardial fibrosis, and impaired systolic and diastolic function, hallmarks of diabetic cardiomyopathy.

DCM often remains clinically silent in early stages, making timely diagnosis challenging. However, its

Citation: chohan A. Unveiling diabetic cardiomyopathy: Pathophysiology and clinical implications. J Diabetol. 2025;9(1):249

progression can lead to heart failure, arrhythmias, and increased cardiovascular mortality.

Patients may initially present with subtle signs of diastolic dysfunction such as exertional dyspnea or fatigue. As the disease advances, symptoms of congestive heart failure, including peripheral edema, orthopnea, and reduced exercise tolerance, become prominent.

Since DCM is a diagnosis of exclusion, clinicians must rule out coronary artery disease, hypertension, and valvular heart disease. Echocardiography is the cornerstone for detecting functional abnormalities, especially diastolic dysfunction and ventricular hypertrophy. Advanced imaging like cardiac MRI can assess myocardial fibrosis. Biomarkers such as brain natriuretic peptide (BNP) levels may assist in evaluating heart failure severity.

Management focuses on tight glycemic control to reduce hyperglycemia-induced myocardial damage. Recent evidence suggests that sodium-glucose cotransporter-2 (SGLT2) inhibitors not only improve glycemic control but also confer direct cardiovascular benefits by reducing heart failure hospitalizations in diabetic patients.

DCM significantly increases the risk of heart failure and cardiovascular mortality among diabetic patients. Early detection and intervention are crucial to slow disease progression and improve survival.

Ongoing research aims to elucidate novel molecular pathways involved in DCM and develop targeted therapies. Biomarkers for early detection and risk stratification are under investigation. Furthermore, personalized medicine approaches integrating genetics and metabolic profiling hold promise for optimizing treatment [5].

Conclusion

Diabetic cardiomyopathy is a complex cardiac complication of diabetes with distinct pathophysiological mechanisms including metabolic derangements, inflammation, fibrosis, and microvascular dysfunction. Its insidious onset and progression to heart failure make early recognition vital. Integrating tight glycemic control, cardiovascular risk management, and emerging therapeutics can improve outcomes in patients with diabetic cardiomyopathy. As the diabetes epidemic grows, advancing our understanding and management of this condition remains a healthcare imperative.

References

1. Fried JL, Maxey HL, Battani K, et al. Preparing the future dental hygiene workforce: knowledge, skills, and reform. J Dent Educ. 2017;81(9):eS45-52.
2. Yazdanian M, Rostamzadeh P, Rahbar M, et al. The potential application of green-synthesized metal nanoparticles in dentistry: A comprehensive review. Bioinorganic Chemistry and Applications. 2022;2022.
3. Sharan J, Singh S, Lale SV, et al. Applications of nanomaterials in dental science: A review. J Nanosci 2017;17(4):2235-55.
4. Abou Neel EA, Bozec L, Perez RA, et al. Nanotechnology in dentistry: prevention, diagnosis, and therapy. int j nanomed. 2015:6371-94.
5. Noronha VT, Paula AJ, Durán G, et al. Silver nanoparticles in dentistry. Dental Materials. 2017;33(10):1110-26.

Citation: chohan A. Unveiling diabetic cardiomyopathy: Pathophysiology and clinical implications. J Diabetol. 2025;9(1):249